Anti−Hepatitis C Virus Drugs in Development

Slides:



Advertisements
Similar presentations
HIV Replication Rachel Carriger Biochemistry Fall 2004.
Advertisements

Inside of cell Interior of rough endoplasmic reticulum 5' Receptor protein Signal recognition particle mRNA Ribosome Signal sequence Protein synthesis.
Vaccines and Antivirals. Clinical Use of Interferon Therefore they have been used in the treatment of cancers of various types. Therefore they have been.
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display The Steps in HIV Replication Slide number 1 (1) Viral.
Biochemistry of Hepatitis C
Flaviviridae Positive stranded RNA viruses. Flaviviridae Enveloped virions made up of a lipid bilayer with two or more types of envelope (E) glycoproteins.
Negative-Strand RNA Virus L Proteins: One Machine, Many Activities
Virus Replication John Goulding, Imperial College London, UK
Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response.
Jean Dubuisson, François-Loïc Cosset  Journal of Hepatology 
Roles of Lipoproteins and Apolipoproteins in Particle Formation of Hepatitis C Virus  Takasuke Fukuhara, Chikako Ono, Francesc Puig-Basagoiti, Yoshiharu.
Structural biology of hepatitis C virus
Volume 132, Issue 4, Pages (April 2007)
Hepatitis C Virus NS5A Protein–A Master Regulator?
Objectives To understand the general principles involved in RNA replication discussed in Chapter 6 pages To use the following + stranded RNA viruses.
VIRAL GENE EXPRESSION DR.SOBIA MANZOOR LECTURE 05.
Occult Hepatitis C Virus Infection: Are We Digging Too Deep?
Hepatitis C virus infection
Vineela Chukkapalli, Glenn Randall  Gastroenterology 
Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response.
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Mirjam B. Zeisel, Isabel Fofana, Samira Fafi-Kremer, Thomas F. Baumert 
SMAD About Hepatitis C Virus Cell Entry and Liver Disease
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
HCV NS5A Inhibitors: The Devil Is in the Details
Reciprocal Effects of Micro-RNA-122 on Expression of Heme Oxygenase-1 and Hepatitis C Virus Genes in Human Hepatocytes  Ying Shan, Jianyu Zheng, Richard.
Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes
Volume 142, Issue 6, Pages (May 2012)
Figure 1 HCV life cycle and site of action of DAAs
Is HCV Infection a Neurologic Disorder?
Hepatitis C Virus NS5A Protein–A Master Regulator?
Volume 138, Issue 1, Pages 6-12.e2 (January 2010)
Hepatitis C virus entry and glucocorticosteroids
Volume 104, Issue 6, Pages (March 2001)
Volume 154, Issue 1, Pages (January 2018)
A Historical Perspective on Clinical Advances in Pancreatic Diseases
Volume 150, Issue 4, Pages (April 2016)
Ella H. Sklan, Jeffrey S. Glenn  Gastroenterology 
Hepatitis C Virus Replicons Volume 3 and 4
Emerging Therapeutic Targets for Hepatitis C Virus Infection
David Paul, Vanesa Madan, Ralf Bartenschlager  Cell Host & Microbe 
Jean–Michel Pawlotsky, Stéphane Chevaliez, John G. McHutchison 
A. Sidney Barritt, Michael W. Fried  Gastroenterology 
Hepatitis C virus–cell interactions and their role in pathogenesis
Rotaviruses: From Pathogenesis to Vaccination
Timothy M. Block, Ju-Tao Guo  Gastroenterology 
Host-targeting agents for prevention and treatment of chronic hepatitis C – Perspectives and challenges  Mirjam B. Zeisel, Joachim Lupberger, Isabel Fofana,
Autophagy, Microbial Sensing, Endoplasmic Reticulum Stress, and Epithelial Function in Inflammatory Bowel Disease  Arthur Kaser, Richard S. Blumberg 
Replication of human astroviruses.
Protein interactions during the flavivirus life cycle elucidated by MS-based proteomics. Protein interactions during the flavivirus life cycle elucidated.
Pathogenesis of Flavivirus Infections: Using and Abusing the Host Cell
Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet?
Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response.
New therapies on the horizon for hepatitis C
Michael S. Diamond, Theodore C. Pierson  Cell 
Fei Xiao, Jane A. McKeating, Thomas F. Baumert  Journal of Hepatology 
Volume 132, Issue 1, Pages 5-6 (January 2007)
Nat. Rev. Neurol. doi: /nrneurol
Prevalence and Treatment of Hepatitis C Virus Genotypes 4, 5, and 6
Negative-Strand RNA Virus L Proteins: One Machine, Many Activities
Lost in Translation: An Antiviral Plant Defense Mechanism Revealed
Jean Dubuisson, François-Loïc Cosset  Journal of Hepatology 
Simplified overview of the HCV life cycle and sites of direct acting antiviral therapies. Simplified overview of the HCV life cycle and sites of direct.
Novel Therapies for Hepatitis C Virus Based on Lessons From Virology
Volume 155, Issue 6, Pages (December 2018)
Volume 139, Issue 6, Pages e1 (December 2010)
Assembly of infectious hepatitis C virus particles
Understanding How Hepatitis C Virus Builds Its Unctuous Home
Production and Biomedical Application of Flavivirus-like Particles
The hantavirus life cycle.
Presentation transcript:

Anti−Hepatitis C Virus Drugs in Development Esperance A.K. Schaefer, Raymond T. Chung  Gastroenterology  Volume 142, Issue 6, Pages 1340-1350.e1 (May 2012) DOI: 10.1053/j.gastro.2012.02.015 Copyright © 2012 AGA Institute Terms and Conditions

Figure 1 HCV viral lifecycle, HCV polypeptide structure, and cleavage sites. (A) The HCV viral lifecycle. The virus circulates as a highly lipidated lipoviral particle (LVP). The LVP requires several cells surface receptors for entry (step 1) into the hepatocyte, including scavenger receptor class B1 (SR-B1), CD-81, claudin (CLDN1), and occludin (not pictured). Once internalized, the viral genome is uncoated, revealing the naked viral RNA and viral nucleocapsid. The viral RNA is translated by host ribosomes into the viral polypeptide (step 3), which is then cleaved by a combination of host and viral proteases into the 10 viral proteins. Replication occurs at an endoplasmic reticulum membrane−derived replication complex (the membranous web), which includes the lipid droplet (LD) and nonstructural viral proteins NS4A−NS5B (step 4). Viral replication is also dependent on the participation of key host factors, which include miR-122 and cyclophilin A (CypA). The newly synthesized viral RNA is assembled into new LVP by the Golgi apparatus and subsequently released by the cell (steps 5 and 6). (B) HCV viral genome. The viral genome is a positive-sense, single-stranded RNA genome. The 5′ untranslated region (UTR) contains 2 important domains. The internal ribosome entry site (IRES) directs translation in a cap-independent manner. The 5′ UTR also contains 2 recognition sites by miR-122 that are critical for viral replication. After translation, a single viral polypeptide is generated. The structural proteins are cleaved by host proteases. The NS2/3 autoprotease cleaves the NS2−NS3 junction. The NS3/4A protease initially serves as an autoprotease and separates NS3−NS4A, but then subsequently cleaves the remaining nonstructural proteins. Gastroenterology 2012 142, 1340-1350.e1DOI: (10.1053/j.gastro.2012.02.015) Copyright © 2012 AGA Institute Terms and Conditions

Figure 2 NS5B structure and drug targets. NS5B functions as an RdRp. The structure has a right-handed motif, with structural domains including a finger, thumb, and palm domains and an active, or catalytic site, within a palm subdomain. NIs act at the catalytic site, where they mimic host nucleoside triphosphates (NTPs) and are incorporated into the elongating genome, leading to chain termination. NNIs bind the allosteric sites (palm and thumb), blocking viral replication by way of hindering conformational changes required for activity of the catalytic site. From McGovern BH et al.52 Adapted with permission. Gastroenterology 2012 142, 1340-1350.e1DOI: (10.1053/j.gastro.2012.02.015) Copyright © 2012 AGA Institute Terms and Conditions

Gastroenterology 2012 142, 1340-1350. e1DOI: (10. 1053/j. gastro. 2012 Copyright © 2012 AGA Institute Terms and Conditions

Gastroenterology 2012 142, 1340-1350. e1DOI: (10. 1053/j. gastro. 2012 Copyright © 2012 AGA Institute Terms and Conditions